• Citer

Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.

par Marechal, Raphaël ;Mackey, John R;Lai, Raymond;Demetter, Pieter ;Peeters, Marc;Polus, Marc;Cass, Carol E;Salmon, Isabelle ;Devière, Jacques ;Van Laethem, Jean-Luc
Référence Cancer, 116, 22, page (5200-5206)
Publication Publié, 2010-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Gemcitabine (2',2'-difluorodeoxycytidine) administration after resection of pancreatic cancer improves both disease-free survival (DFS) and overall survival (OS). Deoxycytidine kinase (dCK) mediates the rate-limiting catabolic step in the activation of gemcitabine. The authors of this report studied patient outcomes according to the expression of dCK after a postoperative gemcitabine-based chemoradiation regimen.